Coripharma, a new European contract manufacturing and development organization (CDMO), today announced an agreement with STADA to package 700 million tablets annually for three years, starting this month.
Coripharma, a new European contract manufacturing and development organization (CDMO), today announced an agreement with STADA to package 700 million tablets annually for three years, starting this month.
The tablets, atorvastatin and enalapril, are manufactured at one of STADA’s sites, while Coripharma will utilize two of its packaging lines in Hafnarfjordur, Iceland. The companies will co-operate on quality control and market release of product.
The drugs will be marketed by STADA in multiple European countries, including Germany, France, Spain, Italy, the Netherlands and the Nordics.
About STADA
STADA Arzneimittel AG is a leading manufacturer of high-quality pharmaceuticals and sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of more than EUR 2 billion.
About Coripharma
Coripharma is a new European pharmaceutical contract manufacturing and development organization (CDMO), built on solid heritage. In 2018, former Actavis employees and investors acquired the Actavis manufacturing site in Iceland. Coripharma began operations on the site the same year. This was followed by the company’s 2019 acquisition of Actavis’ R&D site in Iceland from Teva in 2019.
With annual production capacity of 1.2 billion units, Coripharma’s experienced team offers contract manufacturing and development services to pharmaceutical companies all over the world.
